Docteur CELINE PEREIRA-GILLION

Bibliographie

• Stable efficacy and safety after switching from intravenous to subcutaneous tocilizumab in a cohort of 200 patients in real life conditions

  2022

  ArticleJoint Bone Spine

• Maintien thérapeutique d’un second anti-TNF alpha dans les spondyloarthrites : étude multicentrique en situation réelle

  2020

  ArticleRevue du Rhumatisme

• Drug maintenance of a second tumor necrosis factor alpha inhibitor in spondyloarthritis patients: A real-life multicenter study

  2019

  ArticleJoint Bone Spine

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation des cabinets

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieux de consultation

• CHRU TROUSSEAU - CHAMBRAY

  Avenue DE LA REPUBLIQUE, 37170 Chambray-lès-Tours

  ☎ 0247474747Hospitalier🏥 Voir cet établissement
  © OpenStreetMap

  📷 Street View ↗🗺️ Maps ↗OSM ↗

• CABINET DU DR CELINE PEREIRA-GILLION

  5 PLACE JEAN JAURES, 37000 Tours

  Libéral
  3 m20 m44 m47 m

  © OpenStreetMap · Photos Wikimedia Commons (CC)

  📷 Street View ↗🗺️ Maps ↗OSM ↗

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Drug maintenance of a second tumor necrosis factor alpha inhibitor in spondyloarthritis patients: A real-life multicenter study

  Joint bone spine · 2019

  📚 7 citations🩺 Clinique🔓 Open Access📄 PDF gratuit ↗
• 2

  Stable efficacy and safety after switching from intravenous to subcutaneous tocilizumab in a cohort of 200 patients in real life conditions

  Joint bone spine · 2022

  📚 2 citations
• 3

  Application of Recommendations Regarding the Use of Subcutaneous Tumor Necrosis Factor Inhibitors in Spondyloarthritis by Rheumatologists in Daily Practice

  The Journal of rheumatology · 2018

  📚 2 citations

  Lire l'abstract Crossref ↓

  Objective.To assess the implementation of European recommendations for use of TNF inhibitors for spondyloarthritis (SpA), rheumatologists’ level of knowledge of and adherence to the recommendations, and potential barriers to the application of recommendations.Methods.We conducted a retrospective study among 42 rheumatologists who initiated a first subcutaneous TNF inhibitor for SpA in 2013 or 2014. Thirty items from national and international recommendations were separated into 3 domains: indication, pretherapeutic monitoring, and management under TNF inhibitors. A standardized data collection procedure was used to gather data from medical files to assess the application of each recommendation. Questionnaires assessing the knowledge, level of adherence to each recommendation, and potential barriers to their implementation were sent to rheumatologists.Results.Rheumatologists applied a mean of 60% of items from domains A and B, but less than 50% from domain C items. Recommendations regarding the search for previous infection and the prevention of future infections were the ones most often applied. However, < 60% of rheumatologists assessed cancer and other diseases before TNF inhibitor initiation. More than 95% of rheumatologists knew of the recommendations and had a high level of adherence. Lack of time, difficulties accessing specialized consultations, and lack of flexibility in the recommendations explained rheumatologists’ difficulties in applying the recommendations.Conclusion.Despite high levels of knowledge of, and adherence to, recommendations for using TNF inhibitors for SpA, rheumatologists’ application was limited because of a lack of human and material resources.

Publications scientifiques (3) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche